Brief: Innate Pharma: Positive Results From Tellomak Phase 2 Study With Lacutamab

Innate Pharma SA

04/06/2024 06:07

June 4 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA PRESENTS POSITIVE RESULTS FROM TELLOMAK
PHASE 2
STUDY WITH LACUTAMAB IN MYCOSIS FUNGOIDES
    * DATA DEMONSTRATE THAT TREATMENT WITH LACUTAMAB RESULTED IN
MEANINGFUL ANTITUMOR ACTIVITY, REGARDLESS OF KIR3DL2 BASELINE
EXPRESSION
    * DATA DEMONSTRATE OVERALL FAVORABLE SAFETY PROFILE

Source text for Workspace:  ID:nBw7zfXTra 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))